Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, today announced their merger to form Calluna Pharma Inc. (Calluna). Calluna has raised EUR 75 million in a series A financing and is backed by Oxitope and Arxx’s existing lead investors, Forbion, Sarsia, p53, and Investinor. The new company will combine expertise in the field of innate immunity, based on damage-associated molecular patterns (DAMPs), with a pipeline of selective antibodies that target inflammatory and fibrotic indications, including several first-in-class clinical candidates.

Calluna is developing novel therapies that harness the transformative potential of the body's immune system. The Company’s unique approach involves precision targeting of upstream innate immune amplifiers, enabling disruption of a comprehensive range of disease-associated downstream signaling pathways while maintaining a favorable safety profile. As a result, Calluna has developed a robust pipeline of selective antibodies, targeting immunological diseases. These include novel therapeutic candidates that fulfil unmet clinical needs across a spectrum of diseases, driven by acute or chronic inflammation and non-resolving tissue fibrosis.

Calluna has four promising therapies in its pipeline. Its clinical stage lead program, CAL101, is a monoclonal antibody that neutralizes the bioactivity of S100A4, a DAMP protein implicated in serious and life-threatening diseases such as idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, rheumatoid arthritis, and severe (steroid insensitive) asthma. Of particular interest is another of its programs, CAL102, a monoclonal antibody neutralizing oxidized phospholipids – these play a significant role in onset and progression of a wide range of acute and chronic inflammatory and fibrotic diseases. CAL102 demonstrated efficacy in several preclinical disease models.

In joining forces, these two key players in the innate immunology space have created an exciting new clinical company that has four promising therapies in its pipeline with excellent preclinical proof-of-concept data. By innovating beyond traditional treatment strategies, Calluna offers clinical candidates with superior efficacy, improved patient tolerance, and minimal adverse side effects which have real potential to redefine patient outcomes.”

John Montana, PhD., Chief Executive Officer, Calluna Pharma

Antoine Boulanger, PhD., Principal at Forbion, added: “The merger of Oxitope Pharma and Arxx Therapeutics to create Calluna Pharma is a prime example of our Forbion Ventures Fund’s strategy where we both build new and enable existing companies. As a result, we recognized the strength of combining these two companies’ pioneering approaches to disrupt the treatment of inflammatory and fibrotic diseases, the complementarity of management skills, and the resulting robust clinical pipeline. We look forward to continuing our support of potentially life changing clinical assets moving into the next phases of clinical development.”

Sveinung Hole, MBA, Managing Partner at Sarsia (ex-Chair at Arxx Therapeutics) and Susanne Stuffers MD, PhD, Managing Partner at p53, commented: “Sarsia and p53 strive to bring cutting edge ideas and therapies from early-phase to clinical development and beyond to benefit patients and transform people’s lives. Calluna Pharma epitomizes this, and we are enthusiastic to join forces with Forbion and to contribute to the success of this new entity.”

The company’s board of directors will include John Montana, Operating Partner (Forbion), as Chief Executive Officer, Antoine Boulanger, Principal (Forbion), Susanne Stuffers (p53), Farzad Abdi-Dezfuli General Partner (Sarsia), and Marco Boorsma, General Partner (Forbion) as Chairman. The Company is raising further financing to develop its pipeline to multiple key clinical milestones over the next 2.5 years. 

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Calluna Pharma. (2024, January 24). Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases. News-Medical. Retrieved on April 18, 2024 from https://www.news-medical.net/news/20240124/Calluna-Pharma-launches-and-announces-EUR-75-million-Series-A-financing-to-develop-novel-therapies-for-inflammatory-and-fibrotic-diseases.aspx.

  • MLA

    Calluna Pharma. "Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases". News-Medical. 18 April 2024. <https://www.news-medical.net/news/20240124/Calluna-Pharma-launches-and-announces-EUR-75-million-Series-A-financing-to-develop-novel-therapies-for-inflammatory-and-fibrotic-diseases.aspx>.

  • Chicago

    Calluna Pharma. "Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases". News-Medical. https://www.news-medical.net/news/20240124/Calluna-Pharma-launches-and-announces-EUR-75-million-Series-A-financing-to-develop-novel-therapies-for-inflammatory-and-fibrotic-diseases.aspx. (accessed April 18, 2024).

  • Harvard

    Calluna Pharma. 2024. Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases. News-Medical, viewed 18 April 2024, https://www.news-medical.net/news/20240124/Calluna-Pharma-launches-and-announces-EUR-75-million-Series-A-financing-to-develop-novel-therapies-for-inflammatory-and-fibrotic-diseases.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.